The 340B Drug Pricing Program is a game changer for federally qualified health centers (FQHCs), which have limited flexible funding streams at their disposal and often use their 340B savings for services that are non-reimbursable. The financial impact of these savings cannot be overstated, as they allow FQHCs to stretch their already scarce federal resources […]
The 340B Drug Pricing Program is entering one of its most consequential periods in years. Congress is actively considering multiple reform proposals, HRSA is moving forward with a proposed rebate model, pharmaceutical manufacturers continue expanding claims data requirements, and litigation over contract pharmacies remains ongoing. Against this rapidly changing backdrop, Advocates for Community Health (ACH) […]
Data has become one of the most powerful tools in healthcare, helping demonstrate impact, improve quality, and inform key policy decisions. For community health centers, the Uniform Data System (UDS) serves as the nation’s annual snapshot of the Health Center Program, which captures key information on the patients served, services provided, workforce, and health outcomes. […]
Advocates for Community Health (ACH) was featured in 340B Report following the release of Senator Bill Cassidy’s discussion draft proposing significant changes to the 340B Drug Pricing Program. In the article, ACH Senior Vice President of Policy and Government Affairs Stephanie Krenrich emphasized ACH’s longstanding support for thoughtful 340B reform while expressing concerns that the […]
The Trump administration’s FY 2027 budget proposal seeks to move 340B program oversight from HRSA to CMS, while significantly increasing its funding. This move could signal a major shift in federal drug pricing policy, reports 340B Report. The proposed reorganization, which includes a 68% funding increase to $20.5 million for the Office of Pharmacy Affairs […]
Advocates for Community Health (ACH) is encouraged by the proposed HHS funding increase for the 340B Drug Pricing Program. Increased funding from $12.2 million to $20.5 million enables greater transparency and accountability across participating providers, and ensures manufacturers aren’t unduly restricting covered entities. ACH has advocated for increased funding for this very reason and looks […]
The drug industry this week celebrated its first federal appeals court victory against a state 340B contract pharmacy access law—a ruling which could face additional challenges, including before the U.S. Supreme Court, reports Shannon Young at 340B Report. The court ruling blocking West Virginia’s 340B contract pharmacy law sparked strong concern from providers and advocacy […]
A new KFF Health News article from Phil Galewitz spotlights Nebraska as an early test case for the impact of the newly enacted “One Big Beautiful Bill Act,” following federal approval of the state’s Medicaid work requirement program. In Nebraska, the policy could affect roughly 72,000 Medicaid expansion enrollees. While state officials say they will […]
Axios reports that the federal 340B drug pricing program—an $81 billion lifeline for safety-net providers—is facing mounting pressure from major pharmaceutical companies and new federal policy shifts. Stephanie Krenrich, who leads policy and government affairs at Advocates for Community Health, was recently interviewed for the article by Maya Goldman. Drugmakers like Eli Lilly and Novo […]
A recent 340B Report article from Luke Zarzecki highlights the ongoing efforts in Washington, D.C., to preserve the 340B drug pricing program for health centers and other safety-net providers. While some lawmakers are exploring 340B reforms, including rebate models and the proposed 340B ACCESS Act, the reality is that 340B is a vital lifeline. 340B […]
